DE
Dr. Eva Agaiby
President and Director of Clinical & Regulatory Affairs
Clinical Investigation SpecialistsTherapeutic Areas
Clinical Investigation Specialists Pipeline
| Drug | Indication | Phase |
|---|---|---|
| GLP-1 Agonist (Semaglutide) Trials | Type 2 Diabetes and Obesity | Phase 3 |
| Type 2 Diabetes, Obesity & Cardiovascular Disease Trial | Cardiometabolic Syndrome | Not Specified |
| Atherosclerotic Cardiovascular Disease (ASCVD) Trial | Cardiovascular Disease Prevention | Not Specified |
| Heart Failure Trial | Heart Failure | Not Specified |
| Psoriasis Trial | Plaque Psoriasis | Not Specified |
| Migraines Trial | Migraine Headaches | Not Specified |
| Pediatric Migraines Trial | Migraine Headaches in Pediatrics | Not Specified |
| Lp(a) Genetic Risk Screening | Heart Attack/Stroke Risk Assessment | Screening/Diagnostic |